Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
Jack Khattar; President, Chief Executive Officer, Secretary, Director; Supernus Pharmaceuticals Inc Timothy Dec; Chief Financial Officer, Senior Vice President; Supernus Pharmaceuticals Inc Good ...
Supernus Pharmaceuticals (SUPN) Receives a Hold from Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) yesterday and set a ...
Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
Supernus Pharmaceuticals Inc (SUPN) reports robust revenue growth and strategic advancements, despite facing market ...
Stifel Nicolaus Remains a Hold on Supernus Pharmaceuticals (SUPN)
Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...
Supernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...
Renovaro Inc: Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) ...